Home > Healthcare > Medical Devices > Diagnostic Devices > Laboratory Developed Tests Market

Laboratory Developed Tests Market Size

  • Report ID: GMI9340
  • Published Date: May 2024
  • Report Format: PDF

Laboratory Developed Tests Market Size

Laboratory Developed Tests Market size was valued at around USD 8.9 billion in 2023 and is estimated to grow at 6.4% CAGR from 2024 to 2032. The increasing incidence of cancer and genetic disorders, coupled with the rising prevalence of infectious and chronic diseases, is driving significant growth in the laboratory developed tests (LDTs) market.

 

As more people are diagnosed with these conditions, there is a growing demand for specialized diagnostic tests that can accurately detect and monitor them. For instance, according to World Health Organization, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. The most common cancers are breast, lung, colon and rectum and prostate cancers. As per the WHO, around 2.26 million deaths were due to breast cancer worldwide in 2020.

 

Additionally, the prevalence of genetic disorders is a significant public health issue, affecting a substantial proportion of the population worldwide. For instance, the CDC highlights that about 65% of people experience health issues due to congenital genetic mutations. These increase in the prevalence underscore the substantial impact of genetic disorders on individuals globally and emphasize the importance of understanding, diagnosing, and managing these conditions effectively.

 

Laboratory developed tests (LDTs) refer to diagnostic tests that are developed, validated, and performed within a single laboratory. These tests are designed to detect a wide range of conditions, from infectious diseases to genetic disorders, and they are often used when commercial tests are not available or do not meet the specific needs of a patient population.

 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Laboratory developed tests market size was valued at USD 8.9 billion in 2023 and is estimated to grow at 6.4% CAGR from 2024 to 2032, owing to increasing incidence of cancer and genetic disorders.

The molecular diagnostics segment in the laboratory developed tests industry generated USD 2.4 billion in 2023, driven by sensitive and specific methods for detecting pathogens and identifying genetic mutations associated with cancer.

North America laboratory developed tests market size reached USD 3.7 billion in 2023, favored by growing burden of chronic diseases, such as diabetes, cardiovascular diseases, and cancer.

23andMe, Inc., Abbott, Bio-Rad Laboratories, Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd., Illumina, Inc., NeoGenomics Laboratories, OPKO Health, Inc., QIAGEN and Quest Diagnostics Incorporated

Laboratory Developed Tests Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 117
  • Countries covered: 23
  • Pages: 100
 Download Free Sample